<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1571">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04558125</url>
  </required_header>
  <id_info>
    <org_study_id>ML42522</org_study_id>
    <nct_id>NCT04558125</nct_id>
  </id_info>
  <brief_title>Low-Dose Tenecteplase in Covid-19</brief_title>
  <official_title>Low-Dose Tenecteplase in Covid-19 Patients With Acture Pulmonary Embolism: A Randomized, Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  There is a knowledge gap associated with the management of patients with COVID-19 lung
           injury and a laboratory picture compatible with disseminated intravascular coagulation
           (DIC). Clinical data to date support that COVID-19 is associated with a prothrombotic
           state that is not simply explained by an influx of more critically ill individuals.

        -  These patients suffer from severe respiratory failure; hypoxemia and ventilator
           dependence are the primary concerns; ARDS with respiratory failure is frequently the
           cause of death. Macroscopic and probable microvascular thromboembolic events are a major
           concern in this population.

        -  When DIC is associated with COVID-19, it predicts a very poor prognosis.

        -  We plan to evaluate the clinical efficacy and safety of low-dose IV bolus tenecteplase
           (TNK) together with anticoagulation compared with control patients on therapeutic
           anticoagulation alone in hospitalized adults diagnosed with COVID-19 and acute
           intermediate-risk PE. We believe that acute PE in the setting of active COVID-19
           infections likely portend a poor prognosis.

        -  Prospective, multicenter, randomized two-arm trial enrolling consecutive patients who
           meet enrollment criteria.

        -  We hope to generate evidence that low-dose TNK together with anticoagulation is
           beneficial in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, double-blind, placebo-controlled study randomizing patients with acute
      intermediate-risk PE who meet enrollment criteria in a 2:1 manner into intervention (TNK)
      versus placebo arms, respectively. We will have up to 6 sites. After 18 patients are
      enrolled, a safety assessment will be performed by an independent Data and Safety Monitoring
      Board, and if a safety issue arises, it will be considered and discussed among the
      investigators. The planned sample size is 45 patients (30 treatment and 15 control). Subjects
      will be assessed daily while hospitalized. Subjects discharged from the hospital will be
      asked to attend study visits at Days 14 and 30 (telephone / telemedicine, clinic or inpatient
      ward).

      The overall objective of the study is to evaluate the clinical efficacy and safety of IV
      bolus tenecteplase (TNK) and therapeutic anticoagulation compared with placebo and
      therapeutic anticoagulation in hospitalized adults diagnosed with COVID-19 infection and
      acute intermediate-risk PE.

      Written informed consent for participation in the study must be obtained before performing
      any study-related procedures (including screening evaluations). Informed Consent Forms for
      enrolled patients and for patients who are not subsequently enrolled will be maintained at
      the study site.

      After informed consent is obtained, screening and assessment procedures will be completed to
      confirm a patient's eligibility for participation in the study. The screening visit will
      include medical history and physical exam, vitals signs. Standard of care (SOC). labs will be
      reviewed. These may include INR, aPTT, PT (if patient is currently taking a anicoagulant),
      CBC with diff, comprehensive chemistry panel, D-dimer and Ferretin.The results of the
      SARS-CoV-2 will be documented. If subject is in child-bearing age and a pregnancy test was
      not done for SOC, a urine pregnancy test will be performed. Electrocadiogram and CTA will be
      reviewed.

      If the patient is determined to be eligible, the study site will obtain the patient's medical
      record number/unique patient identification number, and treatment assignment to either
      interventional (TNK) or placebo arms of the study will be randomly determined. Patients will
      be allocated to the interventional versus placebo arms in a 2:1 manner as per a computer
      generated randomization schedule using permuted blocks of random sizes. The block sizes will
      not be disclosed to ensure concealment. A total of 30 TNK subjects versus 15 placebo controls
      will be enrolled. Randomization will be via Randomize.net, which is an online, central
      randomization service. Allocation concealment will be ensured, as the service will not
      release the randomization code until the patient has been recruited into the trial, which
      takes place after all baseline measurements have been completed.

      Before the study drug/placebo is administered, the following labs will be drawn CBC with
      diff, comprehensive metabolic panel, CRP, IRN and aPTT and Thromboelastography (TEG) 5000.
      Vital signs will be obtained.Shock Index will be calculated, then the infusion will begin.

      At 6 hours after the infusion, a second Shock Index will be calculated. At 24+/- 6 hours afer
      the infusion, a physical exam will be performed, vital signs will be collected, an
      echocardiogram will be performed and safety labs will be collected. TED 5000 will also be
      collected. SOC lab results will be collected from the chart.

      Patients will have follow up visits on Day 14 +/- 2 days and Day 30 +/- 4 days. These visits
      may take place via televisit or in person. We will collect data on adverse events, vital
      signes and new concomitant medications. We will collect SOC lab results.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 8, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent improvement in shock index (HR/SBP) 6 hours after the TNK/placebo bolus.</measure>
    <time_frame>6 hours post TNK/placebo infusion</time_frame>
    <description>For example, a patient may start with a heart rate of 100/min and systolic BP of 100 mm Hg (shock index = 1) and after therapy, HR might be 90, with systolic BP of 110 mm Hg (shock index of 0.81), an improvement of 19%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Clinical status at 24 hours after administration of TNK / placebo based upon 7-point scale.</measure>
    <time_frame>24 +/- 6 hours post TNK/placebo infusion.</time_frame>
    <description>Assessment of patient status using an ordinal scale will be recorded at baseline and once daily in the morning while hospitalized.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Pulmonary Embolism</condition>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>TNKase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNKase infusion plus standard of care which can be heparin or lovenox</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo infusion plus standard of care which can be heparin or lovenox</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNKase</intervention_name>
    <description>Randomized to TNKase or placebo infusion. Both groups with have SOC which will be either heparin infusion or enoxaparin SQ injections.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TNKase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject (or legally authorized representative) provides written informed consent prior
             to administration of TNK/placebo.

          -  Patient has the ability to comply with the study protocol, in the investigator's
             judgment, and understands and agrees to comply with planned TNK infusion versus
             placebo.

          -  Male or non-pregnant female adult ≥18 years of age, but less than 75 years of age at
             time of enrollment.

          -  Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other
             commercial or public health assay in any specimen &lt; 10 days prior to randomization.

          -  Acute intermediate-risk pulmonary embolism defined as:

               -  Presence of acute pulmonary embolism confirmed by diagnostic imaging (computed
                  tomographic angiography, ventilation-perfusion scan, or invasive pulmonary
                  angiography)

               -  Either abnormal right ventricular (RV) function by echocardiography and elevated
                  troponin-I/troponin-T

        Exclusion Criteria:

          -  Age ≥ 75 years

          -  Anticipated transfer to another hospital which is not a study site within 72 hours

          -  Allergy or contraindications to TNK

          -  Contraindications to systemic anticoagulation

          -  Active bleeding

          -  Known significant bleeding risk (recent exposure to aspirin or any other antiplatelet
             therapy is not an exclusion criterion)

          -  While there is no specific hemoglobin cut-off value for enrollment, investigators will
             gauge the severity / stability of the Hgb and exclude patients deemed inappropriate

          -  High-risk (massive) acute PE (PE associated with hypotension (systolic BP &lt; 90 mmHg
             for &gt; 15 min).

          -  PE associated with syncope and any degree of head trauma

          -  PE meeting criteria for intermediate-risk PE and thus for enrollment, but with
             clinical evidence of deterioration such that the investigator deems the patient not
             appropriate for enrollment.

          -  Administration of thrombolytic agent within the previous 7 days

          -  Pulmonary thrombectomy within the previous 30 days

          -  Uncontrolled hypertension defined as systolic blood pressure &gt;180 mm Hg and/or
             diastolic blood pressure &gt;110 mm Hg at randomization

          -  Previous enrollment in this study

          -  Pregnancy, lactation or parturition within the previous 30 days

          -  Platelet count lower than 80,000/mm3

          -  Prior brain surgery

          -  Severe trauma in the prior 2 weeks

          -  Major surgery in the prior 2 weeks

          -  Brain malignancy / metastases, brain tumor in past 5 years

          -  Brain AVM or ruptured aneurysm at any time

          -  Any intracranial pathology that the investigator / consultants feel would place the
             patient at increased risk if the investigational therapy were initiated (non-contrast
             head CT must be performed to exclude acute intracranial pathology [e.g. stroke] if
             patient is intubated and neurologic exam cannot be performed satisfactorily)

          -  Acute myocardial infarction or history of myocardial infarction within the past 3
             weeks or cardiac arrest during hospitalization

          -  Acute or chronic renal failure requiring dialysis

          -  Chronic liver failure (acutely elevated liver function tests not an exclusion
             criterion)

          -  Cardiac tamponade

          -  Bacterial endocarditis at time of study entry

          -  Seizure during pre-hospital course or during hospitalization for COVID-19

          -  Currently on ECMO

          -  Patients, in whom, in the opinion of the investigator, are critically ill from
             concomitant comorbid cardiopulmonary disease, and unlikely to benefit.

          -  Severe ARDS (P/F ratio &lt; 100)

          -  Major GI or GU bleed within the past 3 weeks

          -  Arterial puncture at a non-compressible site within the past 5 days

          -  Lumbar puncture with in past 7 days

          -  Known abdominal or thoracic aneurysm

          -  Known hypersensitivity or allergy to any ingredients of tenecteplase

          -  History of acute ischemic stroke in the last 90 days

          -  History of hemorrhagic stroke

          -  Pregnant

          -  Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency;
             recent oral anticoagulant therapy with INR &gt;1.7

          -  Any other condition that the investigator felt would place the patient at increased
             risk if the investigational therapy were initiated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor E Tapson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ncovid2019.live</url>
    <description>COVID Statistics</description>
  </link>
  <link>
    <url>https://www.cdc.gov/stroke/facts.htm</url>
    <description>CDC Stroke Facts</description>
  </link>
  <link>
    <url>http://www.acc.org/latest-in-cardiology/ten-points-to-remember/2018/01/29/12/45/2018-guidelines-for-the-early-management-of-stroke</url>
    <description>Stroke Early Management Guidelines</description>
  </link>
  <link>
    <url>https://thrombosisuk.org/downloads/T&amp;H%20and%20COVID.pdf</url>
    <description>Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19</description>
  </link>
  <link>
    <url>https://doi.org/10.1101/2020.04.30.20076703</url>
    <description>TEG max clot strength is consistently elevated and may be predictive of COVID-19 status at the time of ICU admission</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT04359277</url>
    <description>A randomized trial of anticoagulation strategies in COVID-19</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT04345848</url>
    <description>Preventing COVID-19 complications with low- and high-dose anticoagulation (COVID-HEP)</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT04344756</url>
    <description>Trial evaluating efficacy and safety of anticoagulation in patients with COVID-19 infection, nested in the Corimmuno-19 Cohort (CORIMMUNO-COAG)</description>
  </link>
  <link>
    <url>https://www.researchgate.net/publication/340140994_Risk_assessment_of_venous_thromboembolism_and_bleeding_in_COVID-19_patients</url>
    <description>Risk assessment of venous thromboembolism and bleeding in COVID-19 patients</description>
  </link>
  <link>
    <url>https://www.researchgate.net/publication/339939319_Clinical_Pathology_of_Critical_Patient_with_Novel_Coronavirus_Pneumonia_COVID-19_Pulmonary_Fibrosis_and_Vascular_Changes_including_Microthrombosis_Formation</url>
    <description>Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19)</description>
  </link>
  <link>
    <url>https://www.semanticscholar.org/paper/Generalized-Odds-Ratios-for-Ordinal-Data-Agresti/f7ac23e686de751706146f8dd926d1f03d1b0255</url>
    <description>Generalized odds ratios for ordinal data</description>
  </link>
  <reference>
    <citation>Morens DM, Daszak P, Taubenberger JK. Escaping Pandora's Box - Another Novel Coronavirus. N Engl J Med. 2020 Apr 2;382(14):1293-1295. doi: 10.1056/NEJMp2002106. Epub 2020 Feb 26.</citation>
    <PMID>32101660</PMID>
  </reference>
  <reference>
    <citation>Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13.</citation>
    <PMID>32073213</PMID>
  </reference>
  <reference>
    <citation>Han H, Yang L, Liu R, Liu F, Wu KL, Li J, Liu XH, Zhu CL. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120. doi: 10.1515/cclm-2020-0188.</citation>
    <PMID>32172226</PMID>
  </reference>
  <reference>
    <citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.</citation>
    <PMID>32031570</PMID>
  </reference>
  <reference>
    <citation>Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24. Erratum in: Lancet Respir Med. 2020 Apr;8(4):e26.</citation>
    <PMID>32105632</PMID>
  </reference>
  <reference>
    <citation>Sebag SC, Bastarache JA, Ware LB. Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome. Curr Pharm Biotechnol. 2011 Sep;12(9):1481-96. Review.</citation>
    <PMID>21401517</PMID>
  </reference>
  <reference>
    <citation>Ware LB, Bastarache JA, Wang L. Coagulation and fibrinolysis in human acute lung injury--new therapeutic targets? Keio J Med. 2005 Sep;54(3):142-9. Review.</citation>
    <PMID>16237276</PMID>
  </reference>
  <reference>
    <citation>Finigan JH. The coagulation system and pulmonary endothelial function in acute lung injury. Microvasc Res. 2009 Jan;77(1):35-8. doi: 10.1016/j.mvr.2008.09.002. Epub 2008 Sep 18. Review.</citation>
    <PMID>18938186</PMID>
  </reference>
  <reference>
    <citation>Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, Maunder RJ. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol. 1991 Oct;261(4 Pt 1):L240-8.</citation>
    <PMID>1928357</PMID>
  </reference>
  <reference>
    <citation>Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2003 Jul;285(1):L20-8. Epub 2003 May 2.</citation>
    <PMID>12730079</PMID>
  </reference>
  <reference>
    <citation>Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med. 2007 Aug;35(8):1821-8.</citation>
    <PMID>17667242</PMID>
  </reference>
  <reference>
    <citation>Moalli R, Doyle JM, Tahhan HR, Hasan FM, Braman SS, Saldeen T. Fibrinolysis in critically ill patients. Am Rev Respir Dis. 1989 Aug;140(2):287-93.</citation>
    <PMID>2504087</PMID>
  </reference>
  <reference>
    <citation>Texereau J, Pene F, Chiche JD, Rousseau C, Mira JP. Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med. 2004 May;32(5 Suppl):S313-9. Review.</citation>
    <PMID>15118537</PMID>
  </reference>
  <reference>
    <citation>Hardaway RM, Williams CH, Marvasti M, Farias M, Tseng A, Pinon I, Yanez D, Martinez M, Navar J. Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Care Med. 1990 Dec;18(12):1413-8.</citation>
    <PMID>2123144</PMID>
  </reference>
  <reference>
    <citation>Hart DA, Whidden P, Green F, Henkin J, Woods DE. Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model. Clin Invest Med. 1994 Apr;17(2):69-76.</citation>
    <PMID>7516275</PMID>
  </reference>
  <reference>
    <citation>Hardaway RM, Harke H, Tyroch AH, Williams CH, Vazquez Y, Krause GF. Treatment of severe acute respiratory distress syndrome: a final report on a phase I study. Am Surg. 2001 Apr;67(4):377-82.</citation>
    <PMID>11308009</PMID>
  </reference>
  <reference>
    <citation>Stringer KA, Hybertson BM, Cho OJ, Cohen Z, Repine JE. Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. Free Radic Biol Med. 1998 Jul 15;25(2):184-8.</citation>
    <PMID>9667494</PMID>
  </reference>
  <reference>
    <citation>Burgos AM, Saver JL. Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke: Meta-Analysis of 5 Randomized Trials. Stroke. 2019 Aug;50(8):2156-2162. doi: 10.1161/STROKEAHA.119.025080. Epub 2019 Jul 18.</citation>
    <PMID>31318627</PMID>
  </reference>
  <reference>
    <citation>Guillermin A, Yan DJ, Perrier A, Marti C. Safety and efficacy of tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-analysis of randomized trials. Arch Med Sci. 2016 Dec 1;12(6):1181-1187. Epub 2016 Mar 31. Review.</citation>
    <PMID>27904506</PMID>
  </reference>
  <reference>
    <citation>Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Franca A, Galiè N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren F, Konstantinides SV; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014 Apr 10;370(15):1402-11. doi: 10.1056/NEJMoa1302097.</citation>
    <PMID>24716681</PMID>
  </reference>
  <reference>
    <citation>Becattini C, Agnelli G, Salvi A, Grifoni S, Pancaldi LG, Enea I, Balsemin F, Campanini M, Ghirarduzzi A, Casazza F; TIPES Study Group. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res. 2010 Mar;125(3):e82-6. doi: 10.1016/j.thromres.2009.09.017. Epub 2009 Oct 14.</citation>
    <PMID>19833379</PMID>
  </reference>
  <reference>
    <citation>Caldicott D, Parasivam S, Harding J, Edwards N, Bochner F. Tenecteplase for massive pulmonary embolus. Resuscitation. 2002 Nov;55(2):211-3.</citation>
    <PMID>12413760</PMID>
  </reference>
  <reference>
    <citation>Burkart DJ, Borsa JJ, Anthony JP, Thurlo SR. Thrombolysis of occluded peripheral arteries and veins with tenecteplase: a pilot study. J Vasc Interv Radiol. 2002 Nov;13(11):1099-102.</citation>
    <PMID>12427808</PMID>
  </reference>
  <reference>
    <citation>Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-1026. doi: 10.1111/jth.14810. Epub 2020 Apr 27.</citation>
    <PMID>32338827</PMID>
  </reference>
  <reference>
    <citation>Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 May;18(5):1094-1099. doi: 10.1111/jth.14817. Epub 2020 Apr 27.</citation>
    <PMID>32220112</PMID>
  </reference>
  <reference>
    <citation>Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, Charney AW, Narula J, Fayad ZA, Bagiella E, Zhao S, Nadkarni GN. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020 Jul 7;76(1):122-124. doi: 10.1016/j.jacc.2020.05.001. Epub 2020 May 6.</citation>
    <PMID>32387623</PMID>
  </reference>
  <reference>
    <citation>Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10.</citation>
    <PMID>32291094</PMID>
  </reference>
  <reference>
    <citation>Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, Jeanpierre E, Rauch A, Labreuche J, Susen S; Lille ICU Haemostasis COVID-19 Group. Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence. Circulation. 2020 Jul 14;142(2):184-186. doi: 10.1161/CIRCULATIONAHA.120.047430. Epub 2020 Apr 24.</citation>
    <PMID>32330083</PMID>
  </reference>
  <reference>
    <citation>Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schröder AS, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S, Becker H, Bredereke-Wiedling H, de Weerth A, Paschen HR, Sheikhzadeh-Eggers S, Stang A, Schmiedel S, Bokemeyer C, Addo MM, Aepfelbacher M, Püschel K, Kluge S. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med. 2020 Aug 18;173(4):268-277. doi: 10.7326/M20-2003. Epub 2020 May 6.</citation>
    <PMID>32374815</PMID>
  </reference>
  <reference>
    <citation>Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, McTaggart RA, Torbey MT, Kim-Tenser M, Leslie-Mazwi T, Sarraj A, Kasner SE, Ansari SA, Yeatts SD, Hamilton S, Mlynash M, Heit JJ, Zaharchuk G, Kim S, Carrozzella J, Palesch YY, Demchuk AM, Bammer R, Lavori PW, Broderick JP, Lansberg MG; DEFUSE 3 Investigators. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018 Feb 22;378(8):708-718. doi: 10.1056/NEJMoa1713973. Epub 2018 Jan 24.</citation>
    <PMID>29364767</PMID>
  </reference>
  <reference>
    <citation>Benedict CR, Refino CJ, Keyt BA, Pakala R, Paoni NF, Thomas GR, Bennett WF. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation. 1995 Nov 15;92(10):3032-40.</citation>
    <PMID>7586274</PMID>
  </reference>
  <reference>
    <citation>Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018 Mar 20;137(12):e67-e492. doi: 10.1161/CIR.0000000000000558. Epub 2018 Jan 31. Review. Erratum in: Circulation. 2018 Mar 20;137(12 ):e493.</citation>
    <PMID>29386200</PMID>
  </reference>
  <reference>
    <citation>Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, Schonewille WJ, Vos JA, Nederkoorn PJ, Wermer MJ, van Walderveen MA, Staals J, Hofmeijer J, van Oostayen JA, Lycklama à Nijeholt GJ, Boiten J, Brouwer PA, Emmer BJ, de Bruijn SF, van Dijk LC, Kappelle LJ, Lo RH, van Dijk EJ, de Vries J, de Kort PL, van Rooij WJ, van den Berg JS, van Hasselt BA, Aerden LA, Dallinga RJ, Visser MC, Bot JC, Vroomen PC, Eshghi O, Schreuder TH, Heijboer RJ, Keizer K, Tielbeek AV, den Hertog HM, Gerrits DG, van den Berg-Vos RM, Karas GB, Steyerberg EW, Flach HZ, Marquering HA, Sprengers ME, Jenniskens SF, Beenen LF, van den Berg R, Koudstaal PJ, van Zwam WH, Roos YB, van der Lugt A, van Oostenbrugge RJ, Majoie CB, Dippel DW; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015 Jan 1;372(1):11-20. doi: 10.1056/NEJMoa1411587. Epub 2014 Dec 17. Erratum in: N Engl J Med. 2015 Jan 22;372(4):394.</citation>
    <PMID>25517348</PMID>
  </reference>
  <reference>
    <citation>Bivard A, Huang X, McElduff P, Levi CR, Campbell BC, Cheripelli BK, Kalladka D, Moreton FC, Ford I, Bladin CF, Davis SM, Donnan GA, Muir KW, Parsons MW. Impact of Computed Tomography Perfusion Imaging on the Response to Tenecteplase in Ischemic Stroke: Analysis of 2 Randomized Controlled Trials. Circulation. 2017 Jan 31;135(5):440-448. doi: 10.1161/CIRCULATIONAHA.116.022582. Epub 2016 Dec 13.</citation>
    <PMID>27965285</PMID>
  </reference>
  <reference>
    <citation>Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, Yan B, Dowling RJ, Parsons MW, Oxley TJ, Wu TY, Brooks M, Simpson MA, Miteff F, Levi CR, Krause M, Harrington TJ, Faulder KC, Steinfort BS, Priglinger M, Ang T, Scroop R, Barber PA, McGuinness B, Wijeratne T, Phan TG, Chong W, Chandra RV, Bladin CF, Badve M, Rice H, de Villiers L, Ma H, Desmond PM, Donnan GA, Davis SM; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015 Mar 12;372(11):1009-18. doi: 10.1056/NEJMoa1414792. Epub 2015 Feb 11.</citation>
    <PMID>25671797</PMID>
  </reference>
  <reference>
    <citation>From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO), Sacks D, Baxter B, Campbell BCV, Carpenter JS, Cognard C, Dippel D, Eesa M, Fischer U, Hausegger K, Hirsch JA, Shazam Hussain M, Jansen O, Jayaraman MV, Khalessi AA, Kluck BW, Lavine S, Meyers PM, Ramee S, Rüfenacht DA, Schirmer CM, Vorwerk D. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018 Aug;13(6):612-632. doi: 10.1177/1747493018778713. Epub 2018 May 22.</citation>
    <PMID>29786478</PMID>
  </reference>
  <reference>
    <citation>Churilov L, Arnup S, Johns H, Leung T, Roberts S, Campbell BC, Davis SM, Donnan GA. An improved method for simple, assumption-free ordinal analysis of the modified Rankin Scale using generalized odds ratios. Int J Stroke. 2014 Dec;9(8):999-1005. doi: 10.1111/ijs.12364. Epub 2014 Sep 4.</citation>
    <PMID>25196780</PMID>
  </reference>
  <reference>
    <citation>Coutts SB, Dubuc V, Mandzia J, Kenney C, Demchuk AM, Smith EE, Subramaniam S, Goyal M, Patil S, Menon BK, Barber PA, Dowlatshahi D, Field T, Asdaghi N, Camden MC, Hill MD; TEMPO-1 Investigators. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke. 2015 Mar;46(3):769-74. doi: 10.1161/STROKEAHA.114.008504. Epub 2015 Feb 12.</citation>
    <PMID>25677596</PMID>
  </reference>
  <reference>
    <citation>DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. 1994 Jul 15-30;13(13-14):1341-52; discussion 1353-6.</citation>
    <PMID>7973215</PMID>
  </reference>
  <reference>
    <citation>Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, Donnan G, Grotta J, Howard G, Kaste M, Koga M, von Kummer R, Lansberg M, Lindley RI, Murray G, Olivot JM, Parsons M, Tilley B, Toni D, Toyoda K, Wahlgren N, Wardlaw J, Whiteley W, del Zoppo GJ, Baigent C, Sandercock P, Hacke W; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014 Nov 29;384(9958):1929-35. doi: 10.1016/S0140-6736(14)60584-5. Epub 2014 Aug 5. Review.</citation>
    <PMID>25106063</PMID>
  </reference>
  <reference>
    <citation>Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, Roy D, Jovin TG, Willinsky RA, Sapkota BL, Dowlatshahi D, Frei DF, Kamal NR, Montanera WJ, Poppe AY, Ryckborst KJ, Silver FL, Shuaib A, Tampieri D, Williams D, Bang OY, Baxter BW, Burns PA, Choe H, Heo JH, Holmstedt CA, Jankowitz B, Kelly M, Linares G, Mandzia JL, Shankar J, Sohn SI, Swartz RH, Barber PA, Coutts SB, Smith EE, Morrish WF, Weill A, Subramaniam S, Mitha AP, Wong JH, Lowerison MW, Sajobi TT, Hill MD; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015 Mar 12;372(11):1019-30. doi: 10.1056/NEJMoa1414905. Epub 2015 Feb 11.</citation>
    <PMID>25671798</PMID>
  </reference>
  <reference>
    <citation>Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM; TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. 2005 Mar;36(3):607-12. Epub 2005 Feb 3.</citation>
    <PMID>15692126</PMID>
  </reference>
  <reference>
    <citation>Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, Fanale C, Libman R, Kwiatkowski TG, Llinas RH, Levine SR, Johnston KC, Buchsbaum R, Levy G, Levin B; Tenecteplase in Stroke Investigators. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010 Apr;41(4):707-11. doi: 10.1161/STROKEAHA.109.572040. Epub 2010 Feb 25.</citation>
    <PMID>20185783</PMID>
  </reference>
  <reference>
    <citation>Howard G, Waller JL, Voeks JH, Howard VJ, Jauch EC, Lees KR, Nichols FT, Rahlfs VW, Hess DC. A simple, assumption-free, and clinically interpretable approach for analysis of modified Rankin outcomes. Stroke. 2012 Mar;43(3):664-9. doi: 10.1161/STROKEAHA.111.632935. Epub 2012 Feb 16.</citation>
    <PMID>22343650</PMID>
  </reference>
  <reference>
    <citation>Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, Ford I, Muir KW. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015 Apr;14(4):368-76. doi: 10.1016/S1474-4422(15)70017-7. Epub 2015 Feb 26.</citation>
    <PMID>25726502</PMID>
  </reference>
  <reference>
    <citation>Huang X, MacIsaac R, Thompson JL, Levin B, Buchsbaum R, Haley EC Jr, Levi C, Campbell B, Bladin C, Parsons M, Muir KW. Tenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials. Int J Stroke. 2016 Jul;11(5):534-43. doi: 10.1177/1747493016641112. Epub 2016 Apr 5.</citation>
    <PMID>27048693</PMID>
  </reference>
  <reference>
    <citation>Jovin TG, Liebeskind DS, Gupta R, Rymer M, Rai A, Zaidat OO, Abou-Chebl A, Baxter B, Levy EI, Barreto A, Nogueira RG. Imaging-based endovascular therapy for acute ischemic stroke due to proximal intracranial anterior circulation occlusion treated beyond 8 hours from time last seen well: retrospective multicenter analysis of 237 consecutive patients. Stroke. 2011 Aug;42(8):2206-11. doi: 10.1161/STROKEAHA.110.604223. Epub 2011 Jul 21.</citation>
    <PMID>21778444</PMID>
  </reference>
  <reference>
    <citation>Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, San Román L, Serena J, Abilleira S, Ribó M, Millán M, Urra X, Cardona P, López-Cancio E, Tomasello A, Castaño C, Blasco J, Aja L, Dorado L, Quesada H, Rubiera M, Hernandez-Pérez M, Goyal M, Demchuk AM, von Kummer R, Gallofré M, Dávalos A; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015 Jun 11;372(24):2296-306. doi: 10.1056/NEJMoa1503780. Epub 2015 Apr 17.</citation>
    <PMID>25882510</PMID>
  </reference>
  <reference>
    <citation>Kate M, Wannamaker R, Kamble H, Riaz P, Gioia LC, Buck B, Jeerakathil T, Smyth P, Shuaib A, Emery D, Butcher K. Penumbral Imaging-Based Thrombolysis with Tenecteplase Is Feasible up to 24 Hours after Symptom Onset. J Stroke. 2018 Jan;20(1):122-130. doi: 10.5853/jos.2017.00178. Epub 2018 Jan 31. Erratum in: J Stroke. 2018 Sep;20(3):415.</citation>
    <PMID>29402060</PMID>
  </reference>
  <reference>
    <citation>Lansberg MG, Cereda CW, Mlynash M, Mishra NK, Inoue M, Kemp S, Christensen S, Straka M, Zaharchuk G, Marks MP, Bammer R, Albers GW; Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution 2 (DEFUSE 2) Study Investigators. Response to endovascular reperfusion is not time-dependent in patients with salvageable tissue. Neurology. 2015 Aug 25;85(8):708-14. doi: 10.1212/WNL.0000000000001853. Epub 2015 Jul 29.</citation>
    <PMID>26224727</PMID>
  </reference>
  <reference>
    <citation>Logallo N, Kvistad CE, Thomassen L. Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke. CNS Drugs. 2015;29(10):811-8. doi: 10.1007/s40263-015-0280-9. Review.</citation>
    <PMID>26387127</PMID>
  </reference>
  <reference>
    <citation>Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, Rønning OM, Thommessen B, Amthor KF, Ihle-Hansen H, Kurz M, Tobro H, Kaur K, Stankiewicz M, Carlsson M, Morsund Å, Idicula T, Aamodt AH, Lund C, Næss H, Waje-Andreassen U, Thomassen L. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017 Oct;16(10):781-788. doi: 10.1016/S1474-4422(17)30253-3. Epub 2017 Aug 2.</citation>
    <PMID>28780236</PMID>
  </reference>
  <reference>
    <citation>Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, Yavagal DR, Ribo M, Cognard C, Hanel RA, Sila CA, Hassan AE, Millan M, Levy EI, Mitchell P, Chen M, English JD, Shah QA, Silver FL, Pereira VM, Mehta BP, Baxter BW, Abraham MG, Cardona P, Veznedaroglu E, Hellinger FR, Feng L, Kirmani JF, Lopes DK, Jankowitz BT, Frankel MR, Costalat V, Vora NA, Yoo AJ, Malik AM, Furlan AJ, Rubiera M, Aghaebrahim A, Olivot JM, Tekle WG, Shields R, Graves T, Lewis RJ, Smith WS, Liebeskind DS, Saver JL, Jovin TG; DAWN Trial Investigators. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018 Jan 4;378(1):11-21. doi: 10.1056/NEJMoa1706442. Epub 2017 Nov 11.</citation>
    <PMID>29129157</PMID>
  </reference>
  <reference>
    <citation>Parsons MW, Levi CR. Reperfusion trials for acute ischaemic stroke. Lancet. 2012 Aug 25;380(9843):706-8. doi: 10.1016/S0140-6736(12)61043-5. Epub 2012 Jun 28.</citation>
    <PMID>22748819</PMID>
  </reference>
  <reference>
    <citation>Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46-e110. doi: 10.1161/STR.0000000000000158. Epub 2018 Jan 24. Review. Erratum in: Stroke. 2018 Mar;49(3):e138. Stroke. 2018 Apr 18;:.</citation>
    <PMID>29367334</PMID>
  </reference>
  <reference>
    <citation>Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, Albers GW, Cognard C, Cohen DJ, Hacke W, Jansen O, Jovin TG, Mattle HP, Nogueira RG, Siddiqui AH, Yavagal DR, Devlin TG, Lopes DK, Reddy V, du Mesnil de Rochemont R, Jahan R; SWIFT PRIME Investigators. Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke. Int J Stroke. 2015 Apr;10(3):439-48. doi: 10.1111/ijs.12459.</citation>
    <PMID>25777831</PMID>
  </reference>
  <reference>
    <citation>Ovbiagele B, Goldstein LB, Higashida RT, Howard VJ, Johnston SC, Khavjou OA, Lackland DT, Lichtman JH, Mohl S, Sacco RL, Saver JL, Trogdon JG; American Heart Association Advocacy Coordinating Committee and Stroke Council. Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association. Stroke. 2013 Aug;44(8):2361-75. doi: 10.1161/STR.0b013e31829734f2. Epub 2013 May 22. Erratum in: Stroke. 2015 Jul;46(7):e179.</citation>
    <PMID>23697546</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 19, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2020</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Victor Tapson, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

